Key Points The biotech notched a new all-time high for net sales in its third quarter. This growth was powered by sales of its foundational glaucoma products. 10 stocks we like better than Glaukos › Glaukos (NYSE: GKOS), a biotech and pharmaceutical company focused on eye disorders, was the focus of the right kind of investor attention on Thursday. Market players bid the company's stock up by nearly 14% that trading session, thanks almost entirely to a solid quarterly earnings report. The stock's pe ...